In conclusion, the serum level of PLAC1 in breast cancer subjects with DCIS, HER2+, triple-negative and ER+/PR+ subtypes was a sensitive indicator of disease in 40–60 percent of subjects based on the mean+2 SD of levels in control subjects. This evidence concerns the gene ESR1 and breast carcinoma.